The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
APPLIED GENETIC TECHNOL CORP COM 03820J100 5,517 1,455,904 SH   SOLE   1,455,904 0 0
CIDARA THERAPEUTICS INC COM 171757107 2,279 1,356,813 SH   SOLE   1,356,813 0 0
EIGER BIOPHARMACEUTICALS INC COM 28249U105 8,108 764,918 SH   SOLE   764,918 0 0
GLAUKOS CORP COM 377322102 602 7,995 SH   SOLE   7,995 0 0
KALVISTA PHARMACEUTICALS INC COM 483497103 8,611 388,766 SH   SOLE   388,766 0 0
MACROGENICS INC COM 556099109 18,232 1,074,316 SH   SOLE   1,074,316 0 0
OBALON THERAPEUTICS INC COM 67424L100 2,483 3,552,239 SH   SOLE   3,552,239 0 0
XENON PHARMACEUTICALS INC COM 98420N105 82 8,293 SH   SOLE   8,293 0 0
RESTORATION ROBOTICS INC COM 76133C103 3,267 5,355,786 SH   SOLE   5,355,786 0 0
NEURONETICS INC COM 64131A105 12,894 1,030,689 SH   SOLE   1,030,689 0 0
AVEDRO COM 05355N109 53,858 2,742,239 SH   SOLE   2,742,239 0 0
THE REALREAL COM 88339P101 193,748 6,704,080 SH   SOLE   6,704,080 0 0